January 1, 2004AJP Gastrointestinal and Liver Physiology
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation
Key result
In rats, the NO-releasing aspirin NCX-4016 did not cause gastric damage or inflammation when administered alone or coadministered with celecoxib, in contrast to aspirin.
Authors
Discussion
Loading...
Member takes
Implication
Does not support clinical NSAID changes; leaves open gastroprotection by NO-releasing agents in human trials.
PICO
P
Population
Rats treated with aspirin or NCX-4016, alone or with celecoxib, to assess gastric damage and inflammation.
I
Intervention / Comparator
NCX-4016 vs Aspirin
O
Primary Outcome
Gastric damage and inflammation
Cite This Study
Wallace et al. (2004) studied Gastric damage and inflammation. NCX-4016 vs. Aspirin was evaluated on Gastric damage and inflammation. In rats, the NO-releasing aspirin NCX-4016 did not cause gastric damage or inflammation when administered alone or coadministered with celecoxib, in contrast to aspirin.